Skip to main content
. 2018 Mar 9;118(8):1084–1088. doi: 10.1038/s41416-018-0005-1

Table 1.

Summary of numbers and outcomes in the respective arms of the original trials

Trial Arm n mOS (95% CI) Reference
ESPAC- 3(v2) GEM 537 23.6 (21.4–26.4) 4
ESPAC-3(v2) 5FU 551 23.0 (21.1–25.0)
Pooled ESPAC-1/ESPAC-3(v1) OBS 225 16.8 (14.3–19.2) 14

GEM gemcitabine, 5FU 5-fluorouracil with folinic acid, OBS observational arm, mOS median overall survival, 95% CI 95% confidence interval